A structured, phenotype-driven algorithm incorporating biomarkers, imaging, symptom distribution, and metabolic and vascular factors is essential for effective neuromodulation in PDPN. Because small-fiber degeneration, segmental hyperexcitability, and central sensitization vary, no single modality suits all patients; peripheral, segmental, and central options should follow a rational pathway (
42,
43). Phenotype characterization, which incorporates symptom distribution, QST, and structural biomarkers, is the first step in clinical decision-making. Peripheral nerve stimulation is ideal for patients with focal or regionally dominant pain. This approach is also supported by the maintenance of nociceptive thresholds and moderate loss of small fibers. Nerve accessibility and lead placement planning are verified with high-resolution ultrasound (
11,
44). Dorsal root ganglion stimulation is more beneficial for patients with dermatomal pain patterns, segmental hyperexcitability, or mixed sensory loss (
45). DRGS is well suited to stocking-glove neuropathy along sensory pathways. Imaging, particularly fluoroscopy or CT, facilitates safe access to the foramina and allows identification of anatomical constraints (
36). Spinal cord stimulation is indicated for patients who present with diffuse stocking-glove neuropathy, central sensitization, or diffuse sensory loss. Prolonged, high-frequency SCS (10 kHz) covers a wide area and is better supported by evidence for PDPN (
18). MRI is important for assessing canal stenosis, epidural scarring, and CSF thickness, all of which can affect lead placement and the stability of the stimulation field. Closed-loop SCS systems in which feedback is based on ECAP are especially useful for patients with variable neural excitability (
17).
PNS should be assessed periodically by ultrasound, particularly in patients with fluctuating edema or soft-tissue changes, to assess lead stability and proximity to the nerve (
46). DRGS follow-up focuses on confirming dermatomal coverage and adjusting stimulation intensity to reflect changes in ganglion excitability. To maintain stable dorsal column engagement, feedback signals such as ECAPs should be monitored periodically in SCS systems, especially on high-frequency or closed-loop platforms (
47). These assessments may help maintain consistent analgesia and avoid drift in therapy, while long-term outcomes remain critically dependent on concurrent metabolic and vascular management, including glycemic control, lipid stabilization, blood pressure regulation, support of endothelial function, and ongoing surveillance for vascular insufficiency to ensure adequate perfusion around leads and target nerves (
48).
The future of PDPN care is expected to depend on flexible, adaptive treatment pathways. Collectively, these advancements establish neuromodulation as a dynamic, personalized, and mechanistically targeted therapy that can adapt to changes in patient neurophysiology and disease progression.